Sandra Weißmann

1.9k citations

28 papers · 861 indexed · h-index 10

Hematology top 2%
- Acute Myeloid Leukemia Research 14
- Chronic Myeloid Leukemia Treatments 8
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 11
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4
Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment 4
Public Health, Environmental and Occupational Health top 10%
- Acute Lymphoblastic Leukemia research 5
Cancer Research
- Cancer Genomics and Diagnostics 5
Molecular Biology
- Epigenetics and DNA Methylation 3

Co-authors: Wolfgang Kern Torsten Haferlach Claudia Haferlach Susanne Schnittger Alexander Kohlmann Vera Grossmann Tamara Alpermann Frank Dicker
Cited by: Hematology Genetics Pathology and Forensic Medicine
Journals: Blood (16 papers)Leukemia (3 papers)British Journal of Haematology (3 papers)
Partner nations: Germany United States

In The Last Decade

Sandra Weißmann

25 papers receiving 849 citations

Peers

Countries citing papers authored by Sandra Weißmann

Since Specialization

Citations

This map shows the geographic impact of Sandra Weißmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Weißmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Weißmann more than expected).

Fields of papers citing papers by Sandra Weißmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Weißmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Weißmann. The network helps show where Sandra Weißmann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sandra Weißmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandra Weißmann Line = papers co-authored together Sandra Weißmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study. Haematologica ·Catherine McCartney,Sandra Weißmann,Franco Ferrucci,Manja Meggendorfer,Torsten Haferlach,Frank Dicker	2025	0
2	Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis Haematologica ·Armin P. Piehler,Marietta Truger,N Saturno,Sandra Weißmann,Martin Schwonzen,Manja Meggendorfer,Wolfgang Kern,Torsten Haferlach,Gregor Hoermann,Claudia Haferlach	2024	0
3	Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses British Journal of Haematology ·Calogero Vetro,Torsten Haferlach,Sabine Jeromin,Anna Stengel,Melanie Zenger,Niroshan Nadarajah,Constance Baer,Sandra Weißmann,Wolfgang Kern,Manja Meggendorfer,Claudia Haferlach	2018	3
4	TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis Blood ·Anna Stengel,Susanne Schnittger,Sandra Weißmann,M Ramalho,Wolfgang Kern,Alexander Kohlmann,Torsten Haferlach,Claudia Haferlach	2014	109
5	The role of different genetic subtypes of CEBPA mutated AML Leukemia ·Annette Fasan,Claudia Haferlach,Tamara Alpermann,Sabine Jeromin,Vera Grossmann,Christiane Eder,Sandra Weißmann,Frank Dicker,Alexander Kohlmann,Sonja Schindela,Wolfgang Kern,Torsten Haferlach,Susanne Schnittger	2013	116
6	The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL Genes Chromosomes and Cancer ·Vera Grossmann,Claudia Haferlach,Sandra Weißmann,Andreas Roller,Sonja Schindela,С. В. Неклеса,Ebn Ahmady Arezo,Frauke Bellos,Wolfgang Kern,Torsten Haferlach,Susanne Schnittger,Alexander Kohlmann	2013	114
7	SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients Leukemia ·Sabine Jeromin,Sandra Weißmann,Claudia Haferlach,Frank Dicker,RAFAEL MENDONCA DE SOUZA,Vera Grossmann,Tamara Alpermann,Andreas Roller,Alexander Kohlmann,Torsten Haferlach,Wolfgang Kern,Susanne Schnittger	2013	144
8	Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications Journal of Molecular Diagnostics ·Vera Grossmann,Andreas Roller,Hans‐Ulrich Klein,Sandra Weißmann,Wolfgang Kern,Claudia Haferlach,Martin Dugas,Torsten Haferlach,Susanne Schnittger,Alexander Kohlmann	2013	39
9	Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability Blood ·Susanne Schnittger,Niroshan Nadarajah,Tamara Alpermann,Christiane Eder,Alexander Kohlmann,M Ramalho,Sandra Weißmann,Annette Fasan,Maznah Dahlui,Andreia Albuquerque,Sabine Jeromin,Manja Meggendorfer,Frank Dicker,Wolfgang Kern,Claudia Haferlach,Torsten Haferlach	2013	1
10	Acute Lymphoblastic Leukemia (ALL) With Low-Hypodiploid/Near-Triploid Karyotype Is a Specific Clinical Entity Characterized By a High TP53 Mutation Frequency Blood ·Sara Drane,Melanie Zenger,Susanne Schnittger,Sandra Weißmann,С. В. Неклеса,Alexander Kohlmann,Frauke Bellos,Wolfgang Kern,Torsten Haferlach,Claudia Haferlach	2013	2
11	RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases Blood ·Sabine Jeromin,Christiane Eder,Sandra Weißmann,Manja Meggendorfer,Tamara Alpermann,Alexander Kohlmann,Wolfgang Kern,Claudia Haferlach,Torsten Haferlach,Susanne Schnittger	2013	1
12	Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies Blood ·Alexander Kohlmann,M Ramalho,Niroshan Nadarajah,Tamara Alpermann,Sandra Weißmann,Andreas Roller,Andreia Albuquerque,Wolfgang Kern,Claudia Haferlach,Susanne Schnittger,Torsten Haferlach	2013	2
13	TP53 Alterations In CLL - Parameters Influencing The Prognostic Impact: A Study On 3,988 Patients Blood ·Claudia Haferlach,Frank Dicker,Sabine Jeromin,Sandra Weißmann,Andreas Roller,R Thiripurasundari,Tamara Alpermann,Wolfgang Kern,Torsten Haferlach,Alexander Kohlmann,Susanne Schnittger	2013	1
14	First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing Blood ·Alexander Kohlmann,Sandra Weißmann,Jared Shlaes,Vera Grossmann,Wolfgang Kern,Claudia Haferlach,Susanne Schnittger,Torsten Haferlach	2012	2
15	SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients Blood ·Sabine Jeromin,Claudia Haferlach,RAFAEL MENDONCA DE SOUZA,Frank Dicker,Sandra Weißmann,Vera Großmann,Tamara Alpermann,Alexander Kohlmann,Torsten Haferlach,Wolfgang Kern,Susanne Schnittger	2012	4
16	Recurrent ATM and BIRC3 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) and Deletion 11q22-q23 Blood ·Vera Großmann,Alexander Kohlmann,Susanne Schnittger,Sandra Weißmann,Sabine Jeromin,Vovchenko MB,Wolfgang Kern,Torsten Haferlach,Claudia Haferlach	2012	2
17	Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1 Blood ·Vera Großmann,Alexander Kohlmann,Susanne Schnittger,Sandra Weißmann,Frank Dicker,Sabine Jeromin,Zhanji Li,Tamara Alpermann,Wolfgang Kern,Torsten Haferlach,Claudia Haferlach	2012	1
18	Landscape of TET2 mutations in acute myeloid leukemia Leukemia ·Sandra Weißmann,Tamara Alpermann,Vera Grossmann,Andreas Kowarsch,Niroshan Nadarajah,Christiane Eder,Frank Dicker,Annette Fasan,Claudia Haferlach,Torsten Haferlach,Wolfgang Kern,Susanne Schnittger,Alexander Kohlmann	2011	183
19	TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele British Journal of Haematology ·Ulrike Bacher,Sandra Weißmann,Alexander Kohlmann,Sonja Schindela,Tamara Alpermann,Susanne Schnittger,Wolfgang Kern,Torsten Haferlach,Claudia Haferlach	2011	17
20	Gallstone Ileus Diagnosed by Technetium-99m Dimethyliminodiacetic Acid Cholescintigraphy A Case Report Clinical Nuclear Medicine ·Charles M. Elkin,Sandra Weißmann,Leonărd M. Freeman	1984	2

About Sandra Weißmann

Sandra Weißmann is a scholar working on Hematology, Genetics, Cancer Research, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health, having authored 28 papers that have together received 861 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (14 papers), Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (8 papers), Acute Lymphoblastic Leukemia research (5 papers), Cancer Genomics and Diagnostics (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Epigenetics and DNA Methylation (3 papers). The work is most often cited by research in Hematology (525 citations), Genetics (317 citations), Pathology and Forensic Medicine (159 citations), Public Health, Environmental and Occupational Health (252 citations) and Cancer Research (116 citations). Sandra Weißmann has collaborated with scholars based in Germany and United States. Frequent co-authors include Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger, Alexander Kohlmann, Vera Grossmann, Tamara Alpermann, Frank Dicker, Andreas Roller and Annette Fasan. Their work appears in journals such as Blood, Leukemia, British Journal of Haematology, Haematologica and Genes Chromosomes and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact